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Abstract 
Introduction: Omega-3 polyunsaturated fatty acids (PUFAs) have been proven critical 
in the development and management of major depressive disorder (MDD) by a number 
of epidemiological, clinical and preclinical studies, but the molecular mechanisms 
underlying this therapeutic action are yet to be understood. Although eicosapentaenoic 
acid (EPA) seems to be the active component of omega-3 PUFAs’ antidepressant effects, 
the biological research about the difference of specific genetic regulations between EPA 
and docosahexaenoic acid (DHA), the two main components of omega-3 PUFAs, is still 
lacking in human subjects.  
Methods: We conducted a 12-week randomized-controlled trial comparing the effects 
of EPA and DHA on gene expressions of phospholipase A2 (cPLA2) and 
cyclo-oxygenase-2 (COX2), serotonin transporter (5HTT), and Tryptophan hydroxylase 
2 (TPH-2) in 27 MDD patients. In addition, the erythrocyte PUFA compositions and the 
candidate gene expressions were also compared between these 27 MDD patients and 22 
healthy controls. 
Results: EPA was associated with a significant decrease in HAM-D scores (CI: -13 to -21, 
p<0.001) and significant increases in erythrocyte levels of EPA (CI: +1.0% to +2.9%, 
p=0.001) and DHA (CI: +2.9% to +5.6%, p=0.007). DHA treatment was associated with a 
significant decrease in HAM-D scores (CI: -6 to -14, p<0.001) and a significant increase 
in DHA levels (CI: +0.2% to +2.3%, p=0.047), but not of EPA levels. The cPLA2 gene 
expression levels were significantly increased in patients received EPA (1.9 folds, 
p=0.038), but not DHA (1.08 folds, p=0.92). There was a tendency for both EPA and DHA 
groups to decrease COX-2 gene expressions. The gene expressions of COX-2, cPLA2, 
TPH-2 and 5-HTT did not differ between MDD cases and healthy controls. 
Conclusions: EPA differentiates from DHA in clinical antidepressant efficacy and in 
upregulating cPLA2 gene regulations, which supports the clinical observation showing 
the superiority of EPA’s antideresspant effects.  
 
Trial Registration: ClinicalTrials.gov identifier: NCT02615405 
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Introduction 
Omega-3 polyunsaturated fatty acids (ω-3 or n-3 PUFAs), such as eicosapentaenoic 
acid (EPA) and docosahexaenoic acid (DHA), are essential nutritional compounds with 
potential preventive and therapeutic effects against depression (Lin et al., 2012; Sarris 
et al., 2015; Song et al., 2016; Su, 2015a; Su, 2015b; Su and Balanzá-Martínez, 2013; Su 
et al., 2014; Su et al., 2015; Su et al., 2013). Patients with major depressive disorder 
(MDD) have lower levels of omega-3 PUFAs (Lin et al., 2010), and societies that consume 
a larger amount of omega-3 PUFAs have a lower prevalence of MDD (Hibbeln, 1998; 
Tanskanen et al., 2001). More importantly, many clinical trials and meta-analyses (Lin et 
al., 2012; Lin and Su, 2007; Martins et al., 2012; Sublette et al., 2011), if not all (Bloch 
and Hannestad, 2012; Marangell et al., 2003; Silvers et al., 2005), have shown that 
omega-3 PUFAs have antidepressant effects.  
The hypothesized mechanisms underlying PUFAs’ antidepressant effects are their 
action on neurotransmission and neuroinflammation (Song et al., 2016; Su, 2009, 2012, 
2015b). DHA has been shown to regulate neurotransmitters function, including 
serotonin, norepinephrine and dopamine (Chalon, 2006; Kodas et al., 2004; Zimmer et 
al., 2002), which is of relevance to the tranditional monoamine theory of depression. On 
the other hand, EPA is important in regulating immune function by antagonizing 
membrane arachidonic acid (AA, an n-6 PUFA), reducing prostaglandin E2 (PGE2) 
synthesis (Farooqui et al., 2006), and preventing the response to inflammatory stimuli  
(Lu et al., 2010; Moon et al., 2007; Moon and Pestka, 2003), which is link to the 
promising inflammation theory of depression. Cytosolic phospholipase A2 (cPLA2) and 
cyclo-oxygenase-2 (COX2) are the two key enzymes of the PUFA metabolism and PGE2 
synthesis and have been proposed to be critical in modes of action for mood stabilizers 
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in animal studies (Bosetti et al., 2002; Rao et al., 2007; Rao et al., 2008). The mRNA 
expressions of the genes encoding for COX-2 were significantly increased in the 
peripheral blood cells of depressed patients (Galecki et al., 2012). In addition, a genetic 
variation, the BanI GG polymorphism, on cPLA2 has been reported to be associated with 
major depressive disorder (Pae et al., 2004), which has been replicated in a another 
population of depression induced by interferon-alpha therapy (Su et al., 2010). 
Despite the fact that DHA is the major omega-3 PUFA in the brain, EPA seems to be 
the most active component of omega-3 PUFAs’ antidepressant effects (Lin et al., 2012; 
Lin and Su, 2007; Martins et al., 2012; Su et al., 2013; Sublette et al., 2011). Our recent 
study further supports this notion by showing that EPA, but not DHA, pre-treatment 
significantly decreased the incidence of interferon-α-induced depression in HCV 
patients (Su et al., 2014). Indeed, clinical trials using only DHA monotherapy as 
antidepressant strategy have shown conflicting findings: Marangell et al. (Marangell et 
al., 2003) found no benefit over placebo for 2 g/day DHA, but Mischoulon et al. 
(Mischoulon et al., 2008) found a dose-response effect supporting 1 g/day as superior to 
2 g/day or 4 g/day, though the latter study was limited by the lack of a placebo arm. 
However, the mechanistic understanding about the difference in clinical effectiveness 
between EPA and DHA in human subjects is still lacking.  
To our knowledge, there are no studies examining the changes of gene expression 
on serotonin transporter (5HTT), Tryptophan hydroxylase 2 (TPH-2), cPLA2 and COX2 
in patients receiving omega-3 PUFAs as antidepressant monotherapy. Therefore, we 
have specifically conducted a 12-week EPA and DHA interventional study to investigate 
their clinical and biological effects in patients with acute episode of MDD. Our 
hypothesis is that EPA and DHA might have different effects on these gene expressions. 
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Method  
Subjects 
All the subjects were referred from the outpatient psychiatric department at the 
China Medical University Hospital, Taichung, Taiwan, where the Institutional Review 
Board approved the study. Eligible participants were those who met the following 
criteria: (1) the diagnostic criteria of DSM-IV for major depressive disorder, (2) 18 to 65 
years old, (3) pre-study ratings of 18 or greater on the 21-item Hamilton Rating Scale for 
Depression (HAM-D) (Hamilton, 1960) and “mildly” to “moderately” ill on the Global 
Severity Item of the Clinical Global Impression (GCI) scale, (4) physically healthy on 
medical history and physical examination and laboratory parameters within normal 
limits, (5) haven’t received any psychiatric treatment in 2 weeks, (6) competent to 
receive a full explanation of the study and give written informed consent. The exclusion 
criteria for patients were: (1) a recent or past history of other axis-I diagnoses besides 
unipolar major depression, including psychotic disorders, organic mental disorders, 
impulse control disorders, substance use disorder or substance abuse (last 6 months 
prior to the studies), and bipolar disorders; (2) axis-II diagnoses, i.e. borderline and 
antisocial personality disorder; (3) a notable medical comorbidity; (4) acutely suicidal 
ideation and attempt were noted that close monitoring such as hospitalization is 
necessary; and (5) regular consumption of omega-3 PUFA supplements or a habit of 
eating fish equal or more than 4 times per week. This study was registered at 
ClinicalTrials.gov under the identifier NCT02615405. 
Study Design and Recruitment 
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Before entering the study, every eligible patient will be assessed by trained 
psychiatrists for any psychiatric disorders as determined by the Structured 
Mini-International Neuropsychiatric Interview (MINI) (Sheehan et al., 1998) The 
information of translation, validation and instruction of Taiwanese version of MINI can 
be accessed at the website of Taiwanese Society of Psychiatry 
(www.sop.org.tw/dow_a.htm). As secondary analyses of original clinical trials, we 
enrolled and randomized the first 30 from 40 eligible outpatients consented to 
participate in this biological research from a 12-week, double-blind, 
randomized-controlled trial, comparing the antidepressant effects of EPA (3.5 g/d) and 
DHA (1.75 g/d). Twenty-seven of them completed the 12-week trial and were included 
in the analysis. For allocation of the participants following simple double-blind 
randomization procedures, a computer-generated list of random numbers was used. 
The identical capsules were pre-packed in bottles and consecutively numbered 
according to the randomisation schedule by an independent nutritionist. One subjects 
discontinued from the EPA group and 2 from the DHA group. Sociodemographic factors, 
including gender, age, education, marital status, as well as the past psychiatric history, 
substances use history and family history will be recorded. All patients who agreed to 
participate in this study provided their signed written informed consent before 
enrolment.  
MDD patients were assigned randomly to take of 5 identical capsules of EPA (3.5 
g/d) or DHA (1.75 g/d) in a double-blind fashion for 12 weeks. The experimental 
capsules containing concentrated EPA (solely 700-mg EPA) or DHA (solely 350-mg 
DHA); they weighted 1000 mg, were deodorized with orange flavour, and supplemented 
with tertiary-butyl hydroquinone (0.2 mg/g) and tocopherols (2 mg/g) as antioxidants. 
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The sources of EPA and DHA were from anchovy fish body oil (purchased from AK 
BioTech, Ulsan, Korea) and algal vegetable (purchased from DSM Nutritional Products, 
Basel, Switzerland), respectively. The treatment protocol is designed to investigate 
potential different effects of EPA and DHA in therapeutic and biological effects in 
patients with major depression.  
The judgment of concomitant medications for anxiety and insomnia or 
discontinuation from this trial for re-allocation to antidepressant drugs will be based on 
physicians’ clinical judgment. Depressive symptoms (the 21-item HAM-D and the 
21-item Beck Depression Inventory, BDI) (Beck et al., 1996; Hamilton, 1960) were 
assessed for clinical outcomes before therapy (week 0), and at week 1, 2, 4, 8, and 12. 
The dietary habits will be assessed with the Taiwanese version of Mini Nutrition 
Assessment (MNA) (Tsai et al., 2007). 
To compared the baseline gene expression profiles between cases and controls, 
twenty-two healthy controls from eligible volunteers were enrolled after exclusion of 
any psychiatric disorders as determined by the Structured Mini-International 
Neuropsychiatric Interview (MINI) (Sheehan et al., 1998). Sociodemographic factors, 
including gender, age, education, marital status, as well as the past psychiatric history, 
substances use history, and family history were recorded.  
Laboratory Methods 
Blood samples were obtained from venous blood between 08:30 and 09:30 after an 
overnight fasting at weeks 0 and 12. The blood tissues were prepared in 24 hours, 
separating erythrocyte for analysis for individual fatty acids by gas chromatography and 
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RNA extracted from peripheral blood mononuclear cells (PBMCs) for gene expression. 
Laboratory measures were conducted on coded samples by research workers who were 
blind to subjects’ information. 
Fatty acid composition of erythrocyte membranes was analyzed and the level of 
individual fatty acid was measured with gas chromatography of methyl esters (Lipid 
Standards, FAME, Sigma Co., St. Louis, MO, USA). The detailed step-by-step procedures 
have been published and described elsewhere (Chang et al., In Press; Chiu et al., 2003; 
Jadoon et al., 2012; Su et al., 2003; Su et al., 2008; Su et al., 2010; Su et al., 2014). Fatty 
acid profiles were identified by comparing the retention times with those of appropriate 
standard fatty acid methyl esters. The levels of each fatty acid were expressed as a 
percentage of total fatty acids. Researchers who participated in the laboratory were 
blind to the information of coded samples. 
Gene expression of cPLA2 (PLA2G4A), COX-2, and 5-HTT was determined by 
qRT-PCR analysis with the ABI PRISM® Step One Plus™ (Applied Biosystems, Foster City, 
CA). Total RNA from PBMCs was isolated using the RNeasy Mini Kit (Qiagen, CA, USA) 
according to the manufacturer’s method. RNA concentration was determined by 
NanoDrop Spectrophotometer (Nanodrop Technologies). Briefly, 100ng of total RNA was 
reverse transcribed with QuantiTect Reverse Transcription Kit (Qiagen Cat. No.205311), 
and the amplification reactions was performed in triplicate in 25 μl final volumes via 
SYBR Green chemistry on an ABI PRISM® Step One Plus™ (Applied Biosystems, Foster 
City, CA). Gene-specific primers for human were from the Qiagen Quanti Tect Primer 
Assay. The gene sequence (QT) and accession numbers (NM), respectively, were 
QT00085813 and NM_024420 for cPLA2, QT00040586 and NM_000963 for COX-2, 
QT00053886 and NM_173353 for the TPH-2, and QT00058380and NM_001045 for 
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5-HTT. All genes were amplified according to the Real-Time Cycler conditions suggested 
by Qiagen. The GAPDH gene amplification was used as a reference standard to 
normalize the target signal. The QuantiFast SYBR Green conditions were followed by the 
manufacture protocol. Cycle threshold was automatically calculated by manufacturer’s 
software, with an independent average threshold determined for each target and each 
plate. Individual reaction kinetics were analyzed using a five-fold dilution series of total 
RNA to ensure each qRT-PCR did not differ significantly from 100%. The relative 
quantity of mRNA expressions were estimated using 2-△CT, where △CT is defined as [CT 
gene of interest ﹣CT gene of GAPDH] (Schmittgen and Livak, 2008; Winer et al., 1999).  
Data Analyses and Statistics 
The SPSS statistical software (SPSS Inc., Chicago, Illinois, USA), version 15, was used 
to compare continuous variables between case and controls using independent-samples 
t test and to compare continuous variables before and after omega-3 PUFAs intervention 
using paired t test. The categorical clinical variables were analysed using χ2 
(chi-squared) test. P values less than 0.05 were considered statistically significant. 
Whenever appropriate, data were reported as Mean±SD and the error bars were 
represented as standard error of the means (SEM) in the result figures. The ratio of the 
mean changess of gene expression after interventions was estimated as 30%. The power 
calculation was accessed by online software on powerandsamplesize.com website. The 
result of sample size estimation for within subjects (before and after EPA/DHA 
interventions) was a total sample size of 42 (21 in each group) with power of 0.9 
(α=0.05).  
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RESULTS 
MDD versus healthy controls 
The participating subjects included 27 (5 male and 22 female) depressive patients 
with a mean age of 45 ± 13 (S.D.) years, and 22 (5 male and 17 female) healthy controls 
with mean age of 45 ± 12 (S.D.) years. Table 1 presents sociodemographic data, the 
severity of depression, and the levels of EPA and DHA before and after omega-3 PUFA 
levels. There were no significant differences between MDD cases and healthy controls in 
age, gender distribution, education, and body mass index (BMI). Patients with MDD had 
a significantly high BDI scores. In depressive patients, the age of onset was 35 ± 10 (S.D.) 
years and the duration of index episode was 17 ± 20 (S.D.) weeks. Numbers of 
depressive episodes were 1.5 ± 0.6 (S.D.). As compared to controls, patients with MDD 
had significantly lower levels of EPA (CI: -0.10 to -1.17%, p=0.046) and DHA (CI: -1.08 to 
-2.81%, p<0.001) on erythrocyte membranes before omega-3 PUFAs supplements. 
Figure 1 shows the comparisons of gene expressions of cPLA2 (1a), COX-2 (1b), TPH-2 
(1c) and 5-HTT (1d) in peripheral blood mononuclear cells (PBMCs). There were no 
significant differences between MDD patients and healthy controls in all four selected 
gene expressions with RNA extracted from peripheral blood mononuclear cells. 
---------------------------------------------------- 
Insert Table 1 and Figure 1 about Here 
---------------------------------------------------- 
EPA versus DHA treatments 
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Twenty-seven patients with MDD were assigned randomly to receive 12-week 
intervention with EPA (n=14) or DHA (n=13) in a double-blind fashion. Table 2 
presents sociodemographic data, the severity of depression, and the levels of EPA and 
DHA before and after omega-3 PUFA levels. At baseline, there were no significant 
differences between patients and controls in age, gender distribution, marital status, 
education, BMI, duration of index episode, numbers of depressive episodes, HAM-D 
scores, and EPA and DHA levels. After 12-week omega-3 PUFAs treatments, EPA 
treatment was associated with significant decreased HAM-D scores (CI: -13 to -21 points, 
p<0.001) and significant increases in levels of erythrocyte EPA (CI: +1.0% to +2.9%, 
p=0.001) and DHA (CI: +2.9% to +5.6%, p=0.007). DHA treatment was also associated 
with significant decreased HAM-D scores (CI: -6 to -14 points, p<0.001) and an increase 
of DHA levels (CI: +0.2% to +2.3%, p=0.047), but not EPA levels (CI: -0.6% to +1.1%, 
p=0.6). As compared to DHA group, EPA treatment was associated with significant lower 
HAMD scores (CI: -2 to -13 points, p<0.001) and higher EPA levels (CI: +1.0% to +2.7%, 
p=0.01) on erythrocyte membranes at Week 12 (Table 2). EPA and DHA were found 
well tolerated in this population. No participant was withdrawn because of adverse 
events by investigators’ decision.  
---------------------------------------------------- 
Insert Table 2 and Figure 2 about Here 
---------------------------------------------------- 
There were no significant differences between EPA and DHA groups in levels of 
relative expression in any of the 4 genes at baseline (before omega-3 PUFAs treatment). 
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Figure 2 shows the fold changes of cPLA2 (2a), COX-2 (2b), TPH-2 (2c) and 5-HTT (2d) 
gene expressions after 12-week EPA or DHA treatments. MDD patients received EPA 
treatment did significantly change the gene expressions of cPLA2 (1.89 folds, p=0.038), 
but not COX-2 (0.36 folds, p=0.09), TPH-2 (1.18 folds, p=1.00) and 5-HTT (1.46 folds, 
p=0.06). DHA treatment did not significantly change of gene expression of any of the 4 
genes of cPLA2 (1.08 folds, p=0.92), COX-2 (0.36 folds, p=0.14), TPH-2 (0.96 folds, 
p=0.62) and 5-HTT (0.87 folds, p=0.82). Since the fold changes of cPLA2 and COX2 in 
EPA and DHA groups were at the same direction, the combination of both groups (MDD 
patients received omega-3 PUFAs treatment for 12 weeks) did have significant changes 
in gene expressions on cPLA2 and COX-2, but not on TPH-2 and 5-HTT. Specifically, the 
gene expressions of cPLA2 increased and COX-2 decreased significantly after 12-week 
omega-3 PUFAs supplementation as shown in Figure 1.  
Finally, we did the correlation analyses of changes between the score improvement 
in depression and the changes of levels in cPLA2, COX-2, TPH-2 and 5-HTT gene 
expressions and erythrocyte DHA and EPA levels. There were no significant results in 
these correlation analyses.  
DISCUSSION 
The main finding of our current study is that EPA differentiates DHA in clinical 
antidepressant efficacy and in cPLA2 gene regulations. In addition, omega-3 PUFAs 
treatment significantly increased the cPLA2 and decreased COX-2 gene expressions, but 
not TPH-2 nor 5-HTT gene expressions. To our knowledge, this is the first study to 
demonstrate that omega-3 PUFAs as an antidepressant treatment significantly changed 
peripheral blood gene expressions in patients with MDD. Previous clinical trials and 
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meta-analyses have shown that the efficacy of omega-3 fatty acids as antidepressant 
might be dependent on the ratio of EPA and DHA, and have suggested that EPA, rather 
than DHA, might be the most active component of omega-3 PUFAs’ antidepressant 
effects (Lin et al., 2012; Lin and Su, 2007; Martins et al., 2012; Su et al., 2013). The 
different clinical antidepressant effects implied different biological pathways of EPA and 
DHA, and it is now supported by our current study that EPA, but not DHA, significantly 
increased cPLA2 gene epxression after 12-week omega-3 PUFA supplement in the gene 
expression model.  
Consistent to previous studies to show the association between cPLA2 and COX2 
genetic variations and depression (Pae et al., 2004; Su et al., 2010), our findings further 
support the important role of cPLA2 and COX-2 genes in modulation of omega-3 PUFAs’ 
antidepressant effects. In addition, as cPLA2 and COX2 have been proposed to be critical 
in mode of action of mood stabilizers in animal studies (Bosetti et al., 2002; Rao et al., 
2007; Rao et al., 2008), our findings replicate this important pathway in human subjects. 
Omega-3 PUFAs intervention significantly changed gene expressions of cPLA2 and 
COX-2, but not TPH-2 and 5-HTT, indicating the antidepressant effects from omega-3 
PUFAs might be independent from the regulation of monoamine systems. On top of 
several animal studies to show that omega-3 PUFAs can regulate gene expressions that 
play important roles in synaptic plasticity and neuronal function (de Urquiza et al., 2000; 
Kitajka et al., 2004; Puskas and Kitajka, 2006), the gene expression regulation in our 
current study implied that PUFA metabolism and inflammation systems would also play 
a role in antidepressant actions.  
Although MDD patients in EPA group have shown significantly lower HAMD scores 
at week 12, both EPA and DHA significantly decreased HAMD scores after 12-week 
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treatment. Without a placebo comparision, our current study could not ruled out 
potential antidepressant effects from DHA. For example, a recent meta-analysis has 
suggested that both EPA and DHA contribute to antidepressant effects, even though that 
the effects of EPA are stronger (Sublette et al., 2011). In our recent clinical trial to 
demonstrate preventive effects of omega-3 PUFAs in interferon-α-induced depression, 
we found that EPA reduces the incidence of depression while DHA delays the onset of 
depression (Su et al., 2014). In our current study, EPA intervention increased both EPA 
and DHA levels. Theoretically, EPA can be metabolised into DHA, and EPA intervention 
can increase blood and brain levels of DHA (Brenna, 2002), which is particularly 
relevant in this context as we used to identified lower endogenous DHA as a risk factor 
for interferon-α-induced depression (Su, 2015a; Su et al., 2010). Incidentally, in our 
previous animal study, we have demonstrated that a PUFAs dietary intervention is able 
to increase PUFAs levels in both erythrocytes and the brain, thus supporting the notion 
that PUFAs changes measureable in the periphery reflect changes in the brain (Huang et 
al., 2008). These results therefore indicate possible synergetic effects of EPA and DHA 
on depressive symptomatology.  
The secondary finding of this study is that the gene expressions of COX-2, cPLA2, 
TPH-2 and 5-HTT did not differ between MDD cases and healthy controls. This implied 
that the individual variations of gene expression between cases and controls 
(“between-subjects”) might be too large to be a diagnostic biomarker. In contrast, the 
comparisons of gene expression between pre-and post-treatment (“within-subjects”) 
are more suitable to apply peripheral mRNA levels as therapeutic biomarkers. In 
addition, our current study also replicated the significant lower levels of erythrocyte 
EPA and DHA in patients with MDD (Lin et al., 2010). Finally, we chose 3.5 grams of EPA 
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and 1.7 grams of DHA per day because our previous studies conducted in Taiwan have 
shown the effective dose to be between 2.2 g/day and 4.4 g/day for EPA, and 1.2 g/day 
to 2.2 g/day for DHA (Su et al., 2003; Su et al., 2008; Su et al., 2014). In addition, we 
chose EPA with a higher dosage than DHA because the bioavailability of EPA might be 
reduced after metabolizing into DHA and other forms of omega-3 PUFAs, while DHA 
might be more stable regarding its bioavailability. These doses are relatively high, which 
is consistent to the fact that the baseline dietary content of fish is much higher in Taiwan 
than in many Western countries (Hibbeln, 1998). 
Some of the findings may appear difficult to reconcile, but this is part due to the 
inherent limitations of insufficient statistical powers in measuring gene expressions 
with large individual variations, rather than a true inconsistency within findings. For 
example, the significant effects of decreasing COX-2 gene expressions by omega-3 PUFAs 
(combining EPA and DHA) disappeared when the whole group was divided into EPA and 
DHA groups, although there is a tendency of decreasing COX-2 gene expressions by both 
EPA and DHA (Figure 2). In addition, this study is also limited by its relatively small 
sample size. Finally, one might argue the increased cPLA2 activity after EPA treatment 
seems to be unfavorable because cPLA2 could release AA. One explanation is that an 
increased peripheral cPLA2 activity might imply a compensation of decreased cPLA2 
activity and AA levels in the brains. Unfortunately, we only measured these biomarkers 
from periphearal blood tissues, and we did not have brain levels for correlations. Future 
animal studies are warranted to investigate the potential complex biological 
interactions.  
In conclusion, the findings from our current study revealed that EPA differentiates 
DHA in clinical antidepressant efficacy and in cPLA2 gene regulations, which supports 
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the clinical observation showing the superiority of EPA’s antideresspant effects . 
Furthermore, the study further supports the important role of cPLA2 and COX-2 genes 
in omega-3 PUFAs’ antidepressant effects and imply that the antidepressant effects from 
omega-3 PUFAs might be independent from the regulation of monoamine systems.  
ACKNOWLEDGEMENT: The work was supported by the following Grants: 
MOST104-2314-B-039-022-MY2, 104-2314-B-039-050-MY3, 103-2320-B-038-012-MY3, 
103-2320-B-039-036, 103-2320-B-039-039-MY3, 103-2923-B-039-002-MY3, and 
102-2911-I-039-501 from the Ministry of Science and Technology, Taiwan; 
NHRI-EX105-10528NI from the National Health Research Institutes, Taiwan; and 
CMU103-S-03, DMR-103-078, CMU104-S-1603 & CMU104-S44 from the China Medical 
University, Taiwan. We would like to thank Miss Grace Chien and Dr. Palani Mahalakshmi 
for assisting the qRT-PCR experiments and clinical experiments.  
CONFLICT OF INTEREST: There are no financial or other relationships that might 
lead to conflict of interest for all authors.  
HIGHLIGHTS:  
 Despite that docosahexaenoic acid (DHA) is the major omega-3 polyunsaturated 
fatty acids (PUFAs) in the brain, eicosapentaenoic acid (EPA) seems to be the active 
component of omega-3 PUFAs’ antidepressant effects. However, the mechanistic 
understanding about the difference in clinical effectiveness between EPA and DHA 
in human subjects is still lacking.  
 Omega-3 PUFAs treatment significantly increased the cytosolic phospholipase A2 
(cPLA2) and decreased cyclo-oxygenase-2 (COX2) gene expressions, but not 
tryptophan hydroxylase 2 (TPH-2) nor serotonin transporter (5HTT) gene 
expressions, indicating the antidepressant effects from omega-3 PUFAs might be 
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independent from the regulation of monoamine systems. 
 EPA differentiates from DHA in clinical antidepressant efficacy and in upregulating 
cytosolic phospholipase A2 (cPLA2) gene regulations.  
 Future animal studies are warranted to investigate the potential complex biological 
interactions between omega-3 PUFAs and cPLA2 genetic expressions in brains.  
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Table 1. Demographic and clinical characteristics of patients of major depressive 
disorder (MDD) and healthy controls  
 
MDD 
(N=27) 
Healthy controls 
(N=22) 
P* 
Age (years), Mean±SD 45 ± 13 45 ± 12 0.9 
Sex (Male, %) 19% 23% 0.7** 
Education (years), Mean±SD 13 ± 3 12 ± 4 0.8 
Body mass index (kg/m2), 
mean±SD 
22 ± 4 24 ± 5 0.3 
Marriage (Married, %) 67% 68% 0.9** 
Family History of MDD (%) 26% 0% 0.010** 
Baseline BDI scores, Mean±SD 26 ± 11 5 ± 4 <0.001 
HAMD scores, Mean±SD   <0.001 
Week 0 26 ± 5   
Week 12 12 ± 9   
EPA levels (%), Mean±SD    
Week 0 2.82 ± 1.00 3.42± 1.03^ 0.046^ 
Week 12 3.77 ± 1.47#  0.016# 
DHA levels (%), Mean±SD    
Week 0 3.56 ± 0.93 5.50 ± 1.81^ <0.001  ^
Week 12 5.03 ± 1.89#  0.001# 
    
* Differences were compared by the Mann-Whitney test unless otherwise specified. E.g. 
** indicates the results of χ2 (chi-squared) tests. ^ indicates comparisons between MDD 
versus controls. # indicates comparisons between before and after treatment. Difference 
was considered statistically significant if a p-value was equal to or smaller than 0.05.  
Abbreviations: MDD, major depressive disorder; EPA, eicosapentaenoic acid; DHA, 
docosahexaenoic acid; HAMD, the 21-item Hamilton Depression Rating Scale; BDI, Beck 
Depression Inventory  
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Table 2. Demographic and clinical characteristics of MDD patients received EPA and DHA  
 
EPA 
(N=14) 
DHA 
(N=13) 
p* 
Age (years), Mean±SD 44 ± 14 46 ± 12 0.7 
Sex (Male, %) 21% 15% 0.7** 
Education (years), Mean±SD 13 ± 3 12 ± 3 0.3 
Body mass index (kg/m2), 
mean±SD 
23 ± 4 21 ± 3 0.1 
Marriage (Married, %) 57% 77% 0.3** 
Index episode (weeks), Mean±SD 18 ± 13 16 ± 25 0.8 
Numbers of episodes, Mean±SD 1.4 ± 0.5 1.6 ± 0.7 0.3 
Family History of MDD (%) 36% 15% 0.2** 
HAMD scores, Mean±SD    
Week 0 26 ± 5 26 ± 6 0.9 
Week 12 8 ± 9 16 ± 7 0.017 
EPA levels (%), Mean±SD    
Week 0 2.65 ± 0.88 3.01 ± 1.09 0.4 
Week 12 4.67 ± 1.23 2.80 ± 1.03 0.001 
DHA levels (%), Mean±SD    
Week 0 3.45 ± 1.00 3.67 ± 0.88 0.6 
Week 12 5.22 ± 1.98 4.83 ± 1.82 0.3 
    
* Differences were compared by the Mann-Whitney test unless otherwise specified. E.g. 
** indicates the results of χ2 (chi-squared) tests. ^ indicates comparisons between MDD 
versus controls. # indicates comparisons between before and after treatment. Difference 
was considered statistically significant if a p-value was equal to or smaller than 0.05.  
Abbreviations: MDD, major depressive disorder; EPA, eicosapentaenoic acid; DHA, 
docosahexaenoic acid; HAMD, the 21-item Hamilton Depression Rating Scale  
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Legends for Figure 1. The relative gene expressions of PBMCs mRNA of cPLA2 (1a), 
COX-2 (1b), TPH-2 (1c) and 5-HTT (1d) in healthy controls and major depressive 
disorders (MDD) patients before and after omega-3 PUFAs treatment. Results are 
presented as the mean values in columns and SEM in error bars. Differences between 
MDD patients and controls were compared by the Mann-Whitney test. There were no 
significant differences between patients and controls in all four selected gene 
expressions. Differences between pre- and post-treatment of omega-3 PUFAs in MDD 
patients were compared by the paired-t test. The levels of relative fold expressions in 
MDD patients received omega-3 PUFAs did increase in cPLA2 and decrease in COX-2, but 
not in TPH-2 and 5-HTT genes. Difference was considered statistically significant if a 
p-value was equal to or smaller than 0.05*.  
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Legends for Figure 2. The fold changes of relative gene expression of PBMCs mRNA 
of cPLA2 (2a), COX-2 (2b), TPH-2 (2c) and 5-HTT (2d) in major depressive 
disorders (MDD) patients before and after EPA and DHA treatments. Results are 
presented as the mean values in columns and SEM in error bars. The baseline values of 
means of every gene expression are reduced to 1 for reference. The fold changes of  
mRNA expression after omega-3 PUFAs treatments are presented as ratio as comparing 
to the baseline respectively. , The SEM values are calculated as the ratios according to 
their mean values. Differences between pre- and post-treatment are compared by 
paired-t test. MDD patients received EPA treatment did significantly change the gene 
expressions of cPLA2 (1.89 folds, p=0.038), but not COX-2 (0.36 folds, p=0.09), TPH-2 
(1.18 folds, p=1.00) and 5-HTT (1.46 folds, p=0.06). DHA treatment did not significantly 
change of gene expression of any of the 4 genes of cPLA2 (1.08 folds, p=0.92), COX-2 
(0.36 folds, p=0.14), TPH-2 (0.96 folds, p=0.62) and 5-HTT (0.87 folds, p=0.82).  
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